# US Biomarker Technologies Market

> US Biomarker Technologies Market Research Report: By Product (Consumables, Instruments), By Profiling Technology (PCR, Imaging Technology, NGS), By Application (Cancer, Infectious Disease) and By Research Area (Genomics, Proteomics) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.01%
- **2024:** $ 11.27 Billion
- **2025:** $ 12.17 Billion
- **2035:** $ 26.3 Billion
- **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Illumina (US), Qiagen (DE), PerkinElmer (US), Merck KGaA (DE)

**Report ID:** MRFR/LS/11748-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** May 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biomarker-technologies-market-13273

---

## Market Summary

## **US Biomarker Technologies Market Overview**

**As per MRFR analysis, the US Biomarker Technologies Market Size was estimated at 9.74 (USD Billion) in 2023. The US Biomarker Technologies Market Industry is expected to grow from 10.8(USD Billion) in 2024 to 25 (USD Billion) by 2035. The US Biomarker Technologies Market CAGR (growth rate) is expected to be around 7.929% during the forecast period (2025 - 2035).**

### **Key Trends of US Biomarker Technologies Market Highlighted**

In the US Biomarker Technologies Market, several important trends are significantly shaping the landscape. One of the key market drivers is the increasing incidence of chronic diseases, which has heightened the demand for efficient diagnostic tools. The Centers for Disease Control and Prevention (CDC) indicates that chronic illnesses such as heart disease and cancer remain leading causes of death in the United States.

As a result, healthcare providers are increasingly relying on [biomarker technologies](../../../reports/biomarker-technologies-market-6150) to improve early detection and treatment customization, leading to better patient outcomes. Opportunities to be explored include the potential of personalized medicine, where biomarker technologies can facilitate tailored therapeutic strategies. This approach aligns with the national initiative to advance precision medicine, as outlined by the National Institutes of Health (NIH).

There is a growing investment in research and development as well as collaborations between academic institutions and biotech companies, fostering innovation in biomarker identification and validation. Recent trends highlight a strong move towards integrating artificial intelligence and machine learning in biomarker discovery. These technologies not only enhance the efficiency of data analysis but also open avenues for discovering new biomarkers that could lead to groundbreaking treatments.

Furthermore, regulatory agencies like the Food and Drug Administration (FDA) are actively working on frameworks to expedite the review process for biomarker-based diagnostics, thereby supporting their deployment in clinical settings. Overall, the US Biomarker Technologies Market is poised for dynamic growth, driven by advancements in technology, increasing investment in research, and the imperative need for better healthcare solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Biomarker Technologies Market Drivers**

### **Rising Incidence of Chronic Diseases**

The US Biomarker Technologies Market Industry is significantly driven by the increasing occurrence of chronic diseases such as cancer, cardiovascular diseases, and diabetes. Chronic diseases have become a major public health concern in the United States, with the Centers for Disease Control and Prevention (CDC) reporting that 6 in 10 adults in the US live with at least one chronic condition. The National Cancer Institute has also indicated that the total number of new cancer cases is projected to rise to over 1.9 million by the year 2025.

This surge in chronic disease prevalence creates a high demand for advanced biomarker technologies to improve diagnostics and treatment options, subsequently driving market growth. Major companies like Roche and Thermo Fisher Scientific are investing heavily in Research and Development to innovate and enhance biomarker assays aimed specifically at chronic disease management, further boosting the market dynamics.

### **Technological Advancements in Biomarker Discovery**

Technological innovations in biomarker discovery techniques, including genomic sequencing, proteomics, and metabolomics, are transforming the US Biomarker Technologies Market Industry. The National Institutes of Health (NIH) have reported that advancements in next-generation sequencing (NGS) technology have made genetic testing more accessible and cost-effective. This democratization of technology allows for larger datasets and more comprehensive analyses, which are critical for the identification of novel biomarkers.

Companies like Illumina and Qiagen are at the forefront of these advancements, with NGS technologies that are enabling breakthroughs in personalized medicine and targeted therapies.

### **Increased Investment in Precision Medicine**

The shift towards precision medicine has become a significant driver for the US Biomarker Technologies Market Industry, as healthcare providers focus on tailored treatments based on individual patient profiles. The National Research Council emphasizes that investment in precision medicine initiatives is expected to reach $180 billion annually by 2025, indicating strong governmental and private sector support. This growing investment is fostering collaborations between biotechnology firms and pharmaceutical companies, leading to innovative biomarker development and integration into clinical practices.

Established organizations such as Pfizer and Merck are increasingly engaging in partnerships that prioritize biomarker usage in drug development, further catalyzing market growth.

## **US Biomarker Technologies Market Segment Insights**

### **Biomarker Technologies Market Product Insights**

The US Biomarker Technologies Market is experiencing significant growth, particularly in the Product segment, which includes vital components like Consumables and Instruments. Consumables play a crucial role in the laboratory and clinical settings, serving as essential supplies for various biomarker assays and testing protocols. Their consistent demand is attributed to the ongoing research and diagnostics aimed at improving patient outcomes and understanding disease mechanisms.

On the other hand, Instruments represent a major technological component within the market, enabling accurate and efficient analysis of biomarkers. They assist in the automation of laboratory processes and enhance the overall throughput of diagnostic tests. The developments in instrument technologies are driving innovation in the market, fostering advancements in precision medicine, and facilitating targeted therapies.

The growth drivers within the US are largely influenced by the rise in chronic diseases, increasing investment in Research and Development (R&D), and a growing emphasis on personalized medicine. Challenges such as regulatory hurdles and high costs of advanced biomarker tests may impact market dynamics. However, opportunities abound in the form of collaborations between biotechnology firms and research institutions, pushing forward the boundaries of biomarker applications in early disease detection and prognostic evaluation.

As the US continues to dominate in healthcare innovations, both Consumables and Instruments in the Biomarker Technologies Market are projected to thrive, shaping the future of medical diagnostics and treatment strategies across various sectors.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Biomarker Technologies Market Profiling Technology Insights**

The Profiling Technology segment within the US Biomarker Technologies Market is an evolving field that plays a critical role in precision medicine and diagnostics. With an increasing demand for personalized therapies, various technologies such as Polymerase Chain Reaction (PCR), Imaging Technology, and Next-Generation Sequencing (NGS) are gaining prominence. PCR is known for its rapid and accurate amplification of nucleic acids, making it essential for disease detection and molecular diagnostics.

Imaging Technology offers vital insights into biological processes, enabling non-invasive monitoring of disease progression, which is crucial for early intervention, especially in cancer care. NGS has transformed genomic research through its ability to sequence an entire genome, facilitating discoveries in gene function and disease pathways. Together, these technologies contribute significantly toward advancing the field of biomarker discovery, leading to more effective disease management strategies and enhancing patient care in the US healthcare environment.

As such, the Profiling Technology segment is poised to drive substantial growth while addressing the complexities of various diseases through improved diagnostic capabilities and therapeutic developments.

### **Biomarker Technologies Market Application Insights**

The Application segment of the US Biomarker Technologies Market encompasses vital areas such as Cancer and Infectious Disease, which are increasingly important in healthcare and precision medicine. With a significant focus on early detection and monitoring of diseases, the Cancer application is crucial as it helps identify biomarkers that can lead to personalized treatment strategies, ultimately improving patient outcomes.

Infectious Disease applications leverage advanced biomarker technologies to enhance the speed and accuracy of disease diagnosis, facilitating timely interventions crucial for public health management. The growing prevalence of chronic diseases and the rising demand for targeted therapies are key drivers contributing to this segment's expansion. Moreover, advancements in biotechnology, such as next-generation sequencing and proteomics, are unlocking new opportunities for both Cancer and Infectious Disease applications, showcasing their significance in addressing complex health challenges.

Healthcare stakeholders in the US are actively pursuing these innovations, reflecting a robust commitment to improving patient care and outcomes within the US Biomarker Technologies Market. The supportive regulatory frameworks and increased funding for research further bolster the growth prospects in this sector, making it a focal point for industry advancements and breakthroughs.

### **Biomarker Technologies Market Research Area Insights**

The US Biomarker Technologies Market is gaining momentum across various research areas, prominently featuring Genomics and Proteomics. As biotechnology continues to evolve, Genomics has emerged as a critical component in personalized medicine, enabling the analysis of an individual's genetic makeup for tailored therapeutic strategies. This focus on genetic insights aids in disease prevention, diagnosis, and treatment, contributing to the rising demand for genomic technologies within the healthcare sector.

Meanwhile, Proteomics plays a significant role in understanding complex biological systems through the analysis of protein expressions, which is vital for drug development and biomarker discovery. The integration of advanced technologies in these areas is expected to revolutionize disease management, enhance diagnostics, and streamline the Research and Development processes. Growing investments in genomic and proteomic research underscore their importance, driving innovation and laying the foundation for improved patient outcomes.

The advancements in these fields offer vast opportunities, addressing the challenges of disease heterogeneity and ultimately promoting the growth of the US Biomarker Technologies Market.

## **US Biomarker Technologies Market Key Players and Competitive Insights**

### **US Biomarker Technologies Market Key Players and Competitive Insights**

The US Biomarker Technologies Market is a rapidly evolving segment characterized by significant innovation and competitive dynamics driven by a diverse range of players. As healthcare continues to advance through precision medicine, biomarker technologies play a critical role in drug development, diagnostics, and personalized treatment plans. Companies in this space are striving to enhance patient outcomes by integrating sophisticated technologies for discovering, validating, and applying biomarkers across various diseases, particularly in oncology and chronic conditions.

The competitive landscape is marked by strategic collaborations, substantial investments in research and development, and ongoing regulatory advancements, which aim to foster the growth and efficacy of biomarker applications. The market is becoming increasingly competitive as new entrants and established firms vie for market share and customer loyalty by leveraging technology and addressing unmet clinical needs.

### **Key Companies in the US Biomarker Technologies Market Include**

Merck and Co stands out within the US Biomarker Technologies Market due to its robust portfolio and strong market presence. The company focuses on developing innovative biomarker-driven therapies, particularly in oncology, infectious diseases, and autoimmune disorders. Merck's extensive R&D capabilities allow it to not only create novel therapeutic options but also advance biomarker discovery, enhancing patient stratification and treatment protocols. Furthermore, Merck benefits from strategic partnerships and collaborations that extend its reach and influence within the market, enabling it to stay ahead in terms of technological advancements and clinical insights.

The company’s commitment to leveraging biomarker technologies in developing personalized medicine distinguishes it from competitors and solidifies its status as a leader in the US.

Illumina represents another key player in the US Biomarker Technologies Market, renowned for its innovative sequencing technologies and genomic analysis solutions. The company’s key products and services include next-generation sequencing systems, array-based solutions, and software for data analysis, all of which are vital tools for biomarker discovery and validation. Illumina has established a solid market presence, supported by its continuous push for technological advancements and vast applications encompassing oncology, reproductive health, and rare diseases. The company’s strengths lie in its advanced technological platform, extensive customer base, and robust collaborations with research institutes and healthcare organizations.

Furthermore, Illumina has been engaged in strategic mergers and acquisitions to expand its capabilities and product offerings, positioning itself at the forefront of the biomarker technology landscape in the US. Such strategic moves not only bolster its market position but also enhance its ability to cater to the evolving needs of researchers and clinicians in biomarker discovery and application.

#### **Key Companies in the US Biomarker Technologies Market Include**

### **US Biomarker Technologies Market Industry Developments**

The US Biomarker Technologies Market has seen several noteworthy developments recently. In June 2023, Merck and Co. launched a significant biomarker discovery initiative focused on improving diagnostic accuracy for cancer therapies. Illumina announced advancements in next-generation sequencing technology, enhancing the ability to identify potential biomarkers for rare diseases in April 2023. Bio-Rad Laboratories also revealed new multiplex biomarker assays aimed at improving research efficiencies in March 2023.

Additionally, Bio-Rad Laboratories entered into an alliance with Thermo Fisher Scientific to enhance innovation in molecular diagnostics in May 2023. Notably, Roche Diagnostics’ acquisition of a precision medicine startup in August 2022 has strengthened its position in biomarker development. The market is experiencing growth, with companies like Bristol-Myers Squibb and Abbott Laboratories investing heavily in Research and Development to expand their biomarker portfolios.

The increased focus on personalized medicine is fueling demand for advanced biomarker technologies, leading to a positive market valuation. As of October 2023, the ongoing collaborations and acquisitions reflect a thriving environment within the US Biomarker Technologies Market, with companies committed to improving diagnostic and therapeutic capabilities.

## **US Biomarker Technologies Market Segmentation Insights**

### **Biomarker Technologies Market Product Outlook**

### **Biomarker Technologies Market Profiling Technology Outlook**

### **Biomarker Technologies Market Application Outlook**

### **Biomarker Technologies Market Research Area Outlook**

- Genomics
- Proteomics

## Market Drivers

### Rising Incidence of Chronic Diseases

The rising incidence of chronic diseases in the US is a significant driver for the biomarker technologies market. Conditions such as cancer, diabetes, and cardiovascular diseases are becoming increasingly prevalent, necessitating the development of effective diagnostic and therapeutic strategies. According to the CDC, chronic diseases account for approximately 70% of all deaths in the US, highlighting the urgent need for innovative solutions. Biomarkers are essential for early detection and monitoring of these diseases, which can lead to improved patient management and outcomes. As the burden of chronic diseases continues to grow, the demand for biomarker technologies is likely to expand correspondingly.

### Growing Demand for Personalized Medicine

The increasing emphasis on personalized medicine is a pivotal driver for the biomarker technologies market. As healthcare shifts towards tailored treatments, biomarkers play a crucial role in identifying patient-specific therapies. This trend is evidenced by the projected growth of the personalized medicine market, which is expected to reach approximately $2 trillion by 2025. Biomarkers enable healthcare providers to predict treatment responses, thereby enhancing patient outcomes. The integration of biomarker technologies into clinical practice is likely to accelerate, as healthcare systems recognize the value of precision medicine. Consequently, the demand for innovative biomarker solutions is anticipated to rise, propelling the biomarker technologies market forward.

### Regulatory Support for Biomarker Development

Regulatory support for biomarker development is emerging as a vital driver for the biomarker technologies market. Agencies such as the FDA are actively promoting the use of biomarkers in drug development and clinical trials. The establishment of guidelines for biomarker qualification has streamlined the approval process, encouraging pharmaceutical companies to invest in biomarker research. This regulatory environment fosters innovation and enhances the credibility of biomarker technologies. As regulatory frameworks continue to evolve, the biomarker technologies market is likely to benefit from increased collaboration between regulatory bodies and industry stakeholders, facilitating the introduction of new biomarker-based solutions.

### Technological Advancements in Diagnostic Tools

Technological innovations in diagnostic tools are significantly influencing the biomarker technologies market. The development of advanced imaging techniques and high-throughput screening methods has enhanced the ability to identify and validate biomarkers. For instance, the market for diagnostic imaging is projected to grow at a CAGR of around 7% from 2023 to 2028. These advancements facilitate earlier disease detection and more accurate prognoses, which are essential for effective treatment planning. As diagnostic technologies continue to evolve, the biomarker technologies market is expected to benefit from increased adoption and integration of these sophisticated tools into clinical workflows.

### Increased Investment in Research and Development

Investment in research and development (R&D) is a critical driver for the biomarker technologies market. Funding from both public and private sectors is essential for advancing biomarker discovery and validation. In recent years, federal funding for biomedical research has seen a notable increase, with the National Institutes of Health (NIH) budget reaching approximately $45 billion in 2025. This influx of capital supports innovative research initiatives aimed at identifying novel biomarkers for various diseases. As R&D efforts intensify, the biomarker technologies market is expected to experience significant growth, driven by the continuous emergence of new biomarker applications.

## Future Outlook

The [Biomarker Technologies Market](https://www.marketresearchfuture.com/reports/biomarker-technologies-market-6150) is projected to grow at 8.01% CAGR from 2025 to 2035, driven by advancements in precision medicine, increased R&D investments, and rising demand for personalized therapies.

**New opportunities:**

- Development of AI-driven biomarker discovery platforms Expansion of liquid biopsy technologies for early disease detection Partnerships with pharmaceutical companies for companion diagnostics

By 2035, the biomarker technologies market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product: Consumables (Largest) vs. Instruments (Fastest-Growing)

The US biomarker technologies market displays a significant distribution between consumables and instruments, with consumables commanding the largest share. This segment is favored due to its essential role in various diagnostic and research applications, driving consistent demand. Instruments, while smaller in share, are rapidly gaining traction as advancements in technology enhance their capabilities and usability, leading to a dynamic shift in market preferences. Growth trends in the US biomarker technologies market indicate a robust expansion in both consumables and instruments. The consumables segment is propelled by an increase in research initiatives and clinical trials, requiring reliable biomarker tools. Conversely, the instruments segment is characterized by technological innovations and automation, which not only improve efficiency but also lower operational costs, thus attracting investments and fostering faster growth in this area.

Technology: Consumables (Dominant) vs. Instruments (Emerging)

Consumables represent the dominant force in the US biomarker technologies market, characterized by a diverse range of products including reagents, assays, and kits that are vital for testing and analysis. Their widespread adoption across laboratories and healthcare facilities underscores their essential nature and critical role in the diagnostics and research sectors. Meanwhile, instruments are emerging as a vital segment, driven by innovations such as advanced imaging systems and automated analyzers that enhance precision and speed in biomarker detection. As laboratories continue to modernize and incorporate novel technologies, the instruments segment is poised for significant growth, attracting new players to the marketplace and encouraging established companies to innovate further.

### By Profiling Technology: PCR (Largest) vs. NGS (Fastest-Growing)

In the US biomarker technologies market, PCR has established itself as the leading profiling technology, commanding a significant share due to its widespread use in diagnostics and research. Imaging Technology also holds a notable portion of the market, but its growth rate lags behind that of NGS, which is rapidly gaining attention for its advanced capabilities in sequencing and analysis. The growth trends in this segment are driven by increasing demand for more precise and efficient biomarker identification and the rising prevalence of chronic diseases. The advancements in technology, including automation and integration with AI, are anticipated to bolster the adoption of NGS further, positioning it as the fastest-growing segment. Moreover, regulatory approvals and a growing number of research initiatives are set to fuel this growth, making NGS increasingly relevant in clinical settings.

Technology: PCR (Dominant) vs. NGS (Emerging)

PCR remains dominant in the profiling technology landscape, owing to its established methods, cost-effectiveness, and reliability in amplification of DNA. It serves as a cornerstone for various applications ranging from infectious disease diagnostics to genetic testing. On the other hand, NGS is an emerging technology that is transforming the field with its ability to provide comprehensive genomic data rapidly. As a high-throughput method, NGS can sequence an entire genome in a single run, which is appealing for research and clinical diagnostics. While PCR is preferred for its simplicity and speed in specific applications, NGS is rapidly advancing, presenting opportunities for personalized medicine and targeted therapies, reflecting the dynamic nature of the US biomarker technologies market.

### By Application: Cancer (Largest) vs. Infectious Disease (Fastest-Growing)

The application segment of the US biomarker technologies market is predominantly driven by the cancer segment, which holds the largest share. Cancer biomarkers are extensively utilized for diagnostics, screening, and therapeutic monitoring, leading to a significant market presence. On the other hand, the infectious disease segment, while smaller, is rapidly growing, driven by increased demand for quick and accurate testing solutions. This shift is increasingly important as healthcare needs evolve to address global health challenges. In terms of growth trends, the cancer segment benefits from technological advancements and increased funding for cancer research, propelling its market dominance. The infectious disease segment is experiencing rapid growth due to the rising incidence of infectious diseases and the demand for early detection mechanisms. Public health initiatives focusing on disease prevention and rapid diagnosis are also key growth drivers, indicating a dynamic shift within this segment.

Application: Cancer (Dominant) vs. Infectious Disease (Emerging)

The cancer segment is characterized by its comprehensive range of biomarkers used in various diagnostic applications, ensuring robust market stability and revenue growth. It leverages advanced technologies such as next-generation sequencing and personalized medicine, enhancing diagnostic precision. In contrast, the infectious disease segment, marked as emerging, is experiencing rapid innovation driven by urgent healthcare needs and technological advancements. This segment focuses on the development of rapid tests and point-of-care diagnostics that cater to increasing patient demand. While the cancer segment remains dominant, the infectious disease sector is quickly gaining traction, presenting opportunities for growth and expansion in biomarker technologies.

### By Research Area: Genomics (Largest) vs. Proteomics (Fastest-Growing)

In the US biomarker technologies market, Genomics holds the largest market share, driven by advancements in sequencing technologies and a growing emphasis on personalized medicine. This segment is widely utilized in research and clinical settings, enabling significant discoveries in disease mechanisms and treatments. On the other hand, Proteomics is experiencing rapid growth due to its increasing application in drug discovery and development, integrating biological data for better health outcomes. The growth trends in these segments are influenced by several factors. Genomics benefits from continuous technological innovations, reducing costs and expanding access to genomic data. Conversely, the proteomics segment is gaining momentum due to collaborative efforts in research and healthcare, fostering new biomarker development and personalized therapies. The integration of proteomic data with genomic insights is also setting the stage for a more holistic approach to healthcare, further propelling market growth.

Research Area: Genomics (Dominant) vs. Proteomics (Emerging)

Genomics represents the dominant force within the US biomarker technologies market, characterized by its comprehensive application in understanding genetic factors that influence health and disease. The ease of access to genomic tools and technologies has made it a go-to in both research and clinical environments. On the other hand, the emerging Proteomics segment is making strides with its focus on analyzing proteins and their functions, which play crucial roles in cellular processes. Its rapid advancement is fueled by technological breakthroughs and increasing investment in research, making it a key area for future growth. The interplay between genomics and proteomics is enhancing research capabilities and leading to innovative biomarker solutions.

## Competitive Benchmarking

The biomarker technologies market is characterized by a dynamic competitive landscape, driven by advancements in precision medicine, personalized healthcare, and the increasing demand for early disease detection. Major players such as Roche (CH), Thermo Fisher Scientific (US), and Illumina (US) are at the forefront, leveraging their extensive research capabilities and innovative product offerings. Roche (CH) focuses on integrating digital health solutions with its biomarker diagnostics, enhancing patient outcomes through data-driven insights. Meanwhile, Thermo Fisher Scientific (US) emphasizes strategic partnerships and acquisitions to expand its portfolio, particularly in genomic and proteomic technologies, thereby solidifying its market position. Collectively, these strategies foster a competitive environment that prioritizes innovation and collaboration.Key business tactics within the biomarker technologies market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with a mix of established players and emerging companies. This fragmentation allows for diverse offerings and fosters competition, as key players strive to differentiate themselves through technological advancements and customer-centric solutions.
In October Roche (CH) announced a collaboration with a leading tech firm to develop AI-driven biomarker discovery platforms. This strategic move is likely to enhance Roche's capabilities in identifying novel biomarkers, potentially accelerating the development of targeted therapies. The integration of AI into their research processes may also streamline operations and reduce time-to-market for new diagnostic tools.
In September Illumina (US) launched a new sequencing platform designed to improve the accuracy and speed of genomic analysis. This innovation is expected to significantly impact the biomarker landscape by enabling more precise identification of genetic markers associated with various diseases. The introduction of this platform may position Illumina as a leader in the genomic biomarker space, attracting partnerships with research institutions and pharmaceutical companies.
In August Thermo Fisher Scientific (US) completed the acquisition of a biotech firm specializing in liquid biopsy technologies. This acquisition is strategically important as it expands Thermo Fisher's capabilities in non-invasive biomarker testing, aligning with the growing trend towards personalized medicine. The integration of these technologies could enhance their product offerings and provide a competitive edge in the rapidly evolving market.
As of November current trends in the biomarker technologies market include a strong emphasis on digitalization, sustainability, and the integration of AI into research and development processes. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of developing robust, reliable biomarker technologies that meet the demands of an increasingly sophisticated healthcare environment.

## Recent News & Developments

The US Biomarker Technologies Market has seen several noteworthy developments recently. In June 2023, Merck and Co. launched a significant biomarker discovery initiative focused on improving diagnostic accuracy for cancer therapies. Illumina announced advancements in next-generation sequencing technology, enhancing the ability to identify potential biomarkers for rare diseases in April 2023. Bio-Rad Laboratories also revealed new multiplex biomarker assays aimed at improving research efficiencies in March 2023.

Additionally, Bio-Rad Laboratories entered into an alliance with Thermo Fisher Scientific to enhance innovation in molecular diagnostics in May 2023. Notably, Roche Diagnostics’ acquisition of a precision medicine startup in August 2022 has strengthened its position in biomarker development. The market is experiencing growth, with companies like Bristol-Myers Squibb and Abbott Laboratories investing heavily in Research and Development to expand their biomarker portfolios.

The increased focus on personalized medicine is fueling demand for advanced biomarker technologies, leading to a positive market valuation. As of October 2023, the ongoing collaborations and acquisitions reflect a thriving environment within the US Biomarker Technologies Market, with companies committed to improving diagnostic and therapeutic capabilities.

## Report Scope

| MARKET SIZE 2024 | 11.27(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 12.17(USD Billion) |
| MARKET SIZE 2035 | 26.3(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.01% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Illumina (US), Qiagen (DE), PerkinElmer (US), Merck KGaA (DE) |
| Segments Covered | Product, Profiling Technology, Application, Research Area |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative biomarker technologies and diagnostics solutions. |
| Key Market Dynamics | Technological advancements drive innovation in biomarker technologies, enhancing diagnostics and personalized medicine applications. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US biomarker technologies market in 2024?**
A: The overall market valuation was $11.27 Billion in 2024.

**Q: What is the projected market valuation for the US biomarker technologies market by 2035?**
A: The projected market valuation for 2035 is $26.3 Billion.

**Q: What is the expected CAGR for the US biomarker technologies market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during 2025 - 2035 is 8.01%.

**Q: Which companies are considered key players in the US biomarker technologies market?**
A: Key players include Roche, Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, Illumina, Qiagen, PerkinElmer, and Merck KGaA.

**Q: What were the valuations for consumables and instruments in the product segment in 2024?**
A: In 2024, consumables were valued at $5.5 Billion, while instruments were valued at $5.77 Billion.

**Q: What is the projected valuation for the PCR profiling technology segment by 2035?**
A: The projected valuation for the PCR profiling technology segment by 2035 is $8.0 Billion.

**Q: How does the imaging technology segment perform in terms of valuation from 2024 to 2035?**
A: The imaging technology segment was valued at $4.0 Billion in 2024 and is projected to reach $9.5 Billion by 2035.

**Q: What are the projected valuations for cancer and infectious disease applications in 2035?**
A: By 2035, cancer applications are projected to reach $12.5 Billion, while infectious disease applications are expected to reach $13.8 Billion.

**Q: What were the valuations for genomics and proteomics in the research area segment in 2024?**
A: In 2024, genomics was valued at $5.5 Billion, and proteomics was valued at $5.77 Billion.

**Q: What is the projected growth for the NGS profiling technology segment by 2035?**
A: The NGS profiling technology segment is projected to grow from $3.77 Billion in 2024 to $8.8 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biomarker-technologies-market-13273*